ACM
CPIX icon

Anfield Capital Management’s Cumberland Pharmaceuticals CPIX Stock Holding History

Anfield Capital Management’s Portfolio CPIX Stock Details CPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,530
Closed -$23K – 158
2019
Q4 		$23K Buy
+4,530
New +$23.9K 0.01% 259

Other funds holding CPIX

AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BAM
Berkshire Asset Management Wilkes Barre, Pennsylvania $2.33B AUM 19.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Anfield Capital Management's CPIX Position: Q1 2020 in Review

Anfield Capital Management sold out of Cumberland Pharmaceuticals (CPIX) in Q1 2020, closing a stake of 4,530 shares — an estimated $23K sold.

Anfield Capital Management first reported a position in CPIX in Q4 2019 and held it in 1 quarter. The position peaked at $23K in Q4 2019. 26 funds tracked by Wall St. Rank hold CPIX as of Q1 2020.

  • Anfield Capital Management reported no remaining Cumberland Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Anfield Capital Management sold 4,530 Cumberland Pharmaceuticals shares in Q1 2020, an estimated $23K.
  • Anfield Capital Management first reported a position in Cumberland Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Anfield Capital Management's Cumberland Pharmaceuticals position peaked at $23K in Q4 2019.
  • 26 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q1 2020.

Based on Anfield Capital Management's 13F filing for Q1 2020, filed 7 May 2020.